Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Open accessThe DOI matches its Crossref record; 208 of the 208 references it cites were found in a registry or an index.
Abstract
Inflammation contributes to many chronic conditions. It is often associated with circulating pro-inflammatory cytokines and immune cells. GLP-1 levels correlate with disease severity. They are often elevated and can serve as markers of inflammation. Previous studies have shown that oxytocin, hCG, ghrelin, alpha-MSH and ACTH have receptor-mediated anti-inflammatory properties that can rescue cells from damage and death. These peptides have been studied well in the past century. In contrast, GLP-1 and its anti-inflammatory properties have been recognized only recently. GLP-1 has been proven to be a useful adjuvant therapy in type-2 diabetes mellitus, metabolic syndrome, and hyperglycemia. It also lowers HbA1C and protects cells of the cardiovascular and nervous systems by reducing inflammation and apoptosis. In this review we have explored the link between GLP-1, inflammation, and sepsis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, GLP-1 mitigates liver inflammation and fibrosis by inhibiting the NF-κB pathway, reducing the release of pro-inflammatory cytokines such as TNF-α and IL-6, and thus suppressing inflammatory pathways.307,413”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [413]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“By modulating inflammatory responses, GLP-1RAs can help prevent the degeneration of dopamine-producing cells.413”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [413]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment with liraglutide reduced NADPH oxidase activity, increased cAMP-PKA activity, and reduced mesangial expansion in mouse models.69,70”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Inflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 1×
“GLP-1 is also involved in multiple other physiological processes including appetite, cardiovascular function, and inflammation (1).”
Background(2020) · PubMed · Cited by 2,642
2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
The Emerging Evidence of the Parkinson Pandemic
Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-181474 · Cited by 1,977 · cited 1×
“1 Parkinson’s disease The prevalence of Parkinson’s disease has been rising in recent years (79, 80).”
BackgroundPrevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845 · cited 1×
“Since dopamine breaks down to form reactive oxygen species, it may contribute to disease progression (92, 93).”
BackgroundMicroglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557
Alzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · cited 1×
“2 Alzheimer’s disease Alzheimer’s disease is the most common form of dementia; it is responsible for 60–70% of cases (110, 111).”
BackgroundInflammation in neurodegenerative diseases
Amor, S., Puentes, F., Baker, D., & Van Der Valk, P. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03225.x · Cited by 1,355
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281
Rajan, K. B., Weuve, J., Barnes, L. L., McAninch, E. A., Wilson, R. S., & Evans, D. A. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12362 · Cited by 1,268 · cited 1×
“1% from age 75 to 84, and 32% from age 85 and older (112, 116).”
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261 · cited 1×
“Exogenous GLP-1 (7–36) amide administration inhibited IL-1 beta transcription and prevented beta-induced amnesia and cell death (36, 59, 113, 114).”
BackgroundKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062 · cited 1×
“Like the GLPs, the intervening peptides (IP-1 and IP-2) may also have physiological functions (12, 13).”
BackgroundPrevalence of Parkinson’s disease across North America
Marras, C., Beck, J. C., Bower, J. H., Roberts, E., Ritz, B., Ross, G. W., Abbott, R. D., Savica, R., Van Den Eeden, S. K., Willis, A. W., et al. (2018) · npj Parkinson's Disease · doi:10.1038/s41531-018-0058-0 · Cited by 968
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“cAMP activates PKA and Epac-2 signal transduction pathways (22).”
BackgroundThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“Under physiological conditions, GLP- 1 is rapidly degraded by dipeptidyl peptidase-4 (DPP- 4) after it is released (7).”
BackgroundWound Fluid from Chronic Leg Ulcers Contains Elevated Levels of Metalloproteinases MMP-2 and MMP-9
Wysocki, A. B., Staiano-Coico, L., & Grinnell, F. (1993) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12359590 · Cited by 732
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · cited 1×
“Frontiers in Immunology 08 mouse model of Alzheimer’s disease reduced the inflammatory response in the cortex by decreasing the number of activated microglia (60, 65, 107, 124, 125).”
Background(2000) · PubMed · Cited by 683
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Complexity of dopamine metabolism
Meiser, J., Weindl, D., & Hiller, K. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-34 · Cited by 663 · cited 1×
“Since dopamine breaks down to form reactive oxygen species, it may contribute to disease progression (92, 93).”
BackgroundDiabetes and Kidney Disease: Role of Oxidative Stress
Jha, J. C., Banal, C., Chow, B. S. M., Cooper, M. E., & Jandeleit-Dahm, K. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6664 · Cited by 660
Current and projected future economic burden of Parkinson’s disease in the U.S.
Yang, W., Hamilton, J. L., Kopil, C., Beck, J. C., Tanner, C. M., Albin, R. L., Ray Dorsey, E., Dahodwala, N., Cintina, I., Hogan, P., et al. (2020) · npj Parkinson's Disease · doi:10.1038/s41531-020-0117-1 · Cited by 657
Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells.
Goldgaber, D., Harris, H. W., Hla, T., Maciag, T., Donnelly, R. J., Jacobsen, J. S., Vitek, M. P., & Gajdusek, D. C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7606 · Cited by 595 · cited 1×
“In AD, IL-1 beta is significantly increased in the frontal cortex and hippocampus and may contribute to cognitive dysfunction by promoting the synthesis of amyloid precursor protein (117, 118).”
BackgroundGlia and their cytokines in progression of neurodegeneration
Mrak, R. E., & Griffin, W. S. T. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.05.010 · Cited by 592
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 2×
“The intraventricular administration of GLP-1 protects mice from MPTP-induced dopaminergic cell loss (64, 86, 108, 109).”
BackgroundGlucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M., Qu, Q., Tarrasch, J. T., Li, S., Sun Kobilka, T., Kobilka, B. K., et al. (2017) · Nature · doi:10.1038/nature22394 · Cited by 576 · cited 1×
“GLP-1 receptor signaling occurs primarily through the Gas stimulatory G protein (21).”
BackgroundAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530 · cited 8×
“Glucagon-like peptide-1 is produced in the brainstem and has numerous functions, including neuroprotection (59–61) GLP-1 and GLP-1 analogs can cross the blood-brain barrier (62–68) GLP-1 receptors have been observed in the neurons of the nucleus tractus solitarius that project to GLP-1R–expressing regions in the hindb…”
BackgroundInfluentialMaiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Armstrong, A. W., Harskamp, C. T., & Armstrong, E. J. (2012) · Nutrition & Diabetes · doi:10.1038/nutd.2012.26 · Cited by 514
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509 · cited 1×
“Studies in humans should be done (42, 43) (Table 1).”
BackgroundParkinson’s Disease: Etiology, Neuropathology, and Pathogenesis
John van Geest Centre for Brain Repair, D. O. C. N., Kouli, A., Torsney, K. M., Department of Medicine for the Elderly, C. U. H. N. F. T., Clinical Gerontology Unit, D. O. P. H. A. P. C., Kuan, W.-L., & John van Geest Centre for Brain Repair, D. O. C. N. (2018) · Parkinson’s Disease: Pathogenesis and Clinical Aspects · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch1 · Cited by 507
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
Cork, S. C., Richards, J. E., Holt, M. K., Gribble, F. M., Reimann, F., & Trapp, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.07.008 · Cited by 478 · cited 1×
“Glucagon-like peptide-1 is produced in the brainstem and has numerous functions, including neuroprotection (59–61) GLP-1 and GLP-1 analogs can cross the blood-brain barrier (62–68) GLP-1 receptors have been observed in the neurons of the nucleus tractus solitarius that project to GLP-1R–expressing regions in the hindb…”
BackgroundTissue inhibitors of metalloproteinases
Murphy, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-11-233 · Cited by 472
Timmers, L., Henriques, J. P. S., de Kleijn, D. P. V., DeVries, J. H., Kemperman, H., Steendijk, P., Verlaan, C. W. J., Kerver, M., Piek, J. J., Doevendans, P. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.033 · Cited by 470 · cited 1×
“Furthermore, administration of the GLP-1R agonist exendin-4 in vivo and in vitro proved protective (132, 138, 139) (Figure 9).”
BackgroundYusta, B., Baggio, L. L., Estall, J. L., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., & Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.001 · Cited by 446
Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
Gómez-Benito, M., Granado, N., García-Sanz, P., Michel, A., Dumoulin, M., & Moratalla, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00356 · Cited by 437
Inflammatory process in Alzheimer's Disease
Meraz-Ríos, M. A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hernández, J., & Campos-Peña, V. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00059 · Cited by 427 · cited 1×
“In AD, IL-1 beta is significantly increased in the frontal cortex and hippocampus and may contribute to cognitive dysfunction by promoting the synthesis of amyloid precursor protein (117, 118).”
BackgroundDiscovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418
Buteau, J., Foisy, S., Joly, E., & Prentki, M. (2003) · Diabetes · doi:10.2337/diabetes.52.1.124 · Cited by 411 · cited 1×
“(Original by authors of the manuscript): The seven transmembrane alpha-helices are bound to G-protein subunits (19).”
BackgroundThe National Institute of Environmental Health Sciences
Mody, V., & Ray, S. D. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00341-9 · Cited by 406
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Alpha-synuclein biology in Lewy body diseases
Kim, W. S., Kågedal, K., & Halliday, G. M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0073-2 · Cited by 374 · cited 1×
“Most Parkinson’s disease treatments focus on managing symptoms by replacing dopamine and improving dopaminergic signaling, but these treatments fail to address the underlying cellular degeneration (64, 91).”
BackgroundGlucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336
Transgenic mouse models of Alzheimer’s disease.
Elder, G. A., Gama Sosa, M. A., & De Gasperi, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20159 · Cited by 336 · cited 1×
“Mice that express two human mutant genes linked to early-onset Alzheimer’s disease develop a chronic inflammatory response (126).”
BackgroundLiraglutide for weight management: a critical review of the evidence
Mehta, A., Marso, S. P., & Neeland, I. J. (2017) · Obesity Science & Practice · doi:10.1002/osp4.84 · Cited by 311
Hui, H., Nourparvar, A., Zhao, X., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2002-220897 · Cited by 307 · cited 1×
“Adding GLP-1 to neurons increases cAMP, which indicates receptor activation (108, 132, 140).”
BackgroundAlvarez, E., Martínez, M. D., Roncero, I., Chowen, J. A., García‐Cuartero, B., Gispert, J. D., Sanz, C., Vázquez, P., Maldonado, A., De Cáceres, J., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02914.x · Cited by 305
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288
GLUCAGON ANTIBODIES AND AN IMMUNOASSAY FOR GLUCAGON*
Unger, R. H., Eisentraut, A. M., McCall, M. S., & Madison, L. L. (1961) · Journal of Clinical Investigation · doi:10.1172/jci104357 · Cited by 285 · cited 2×
“, developed the first antibody that could be used in a radioimmunoassay to detect glucagon in tissue samples and blood (9, 10).”
BackgroundYusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282
Kimball, C. P., & Murlin, J. R. (1923) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)85474-6 · Cited by 250
Li, Y., Cao, X., Li, L.-X., Brubaker, P. L., Edlund, H., & Drucker, D. J. (2005) · Diabetes · doi:10.2337/diabetes.54.2.482 · Cited by 247 · cited 1×
“Exogenous GLP-1 (7–36) amide administration inhibited IL-1 beta transcription and prevented beta-induced amnesia and cell death (36, 59, 113, 114).”
BackgroundEnteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion
Lebrun, L. J., Lenaerts, K., Kiers, D., Pais de Barros, J.-P., Le Guern, N., Plesnik, J., Thomas, C., Bourgeois, T., Dejong, C. H. C., Kox, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.008 · Cited by 238 · cited 1×
“Frontiers in Immunology 05 1 improves mucosal integrity and diminishes inflammation (42, 46).”
BackgroundBiologic actions and therapeutic potential of the proglucagon-derived peptides
Drucker, D. J. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0017 · Cited by 230 · cited 1×
“Like the GLPs, the intervening peptides (IP-1 and IP-2) may also have physiological functions (12, 13).”
BackgroundHamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227 · cited 1×
“Glucagon-like peptide-1 is produced in the brainstem and has numerous functions, including neuroprotection (59–61) GLP-1 and GLP-1 analogs can cross the blood-brain barrier (62–68) GLP-1 receptors have been observed in the neurons of the nucleus tractus solitarius that project to GLP-1R–expressing regions in the hindb…”
BackgroundPost-sepsis syndrome – an evolving entity that afflicts survivors of sepsis
Mostel, Z., Perl, A., Marck, M., Mehdi, S. F., Lowell, B., Bathija, S., Santosh, R., Pavlov, V. A., Chavan, S. S., & Roth, J. (2020) · Molecular Medicine · doi:10.1186/s10020-019-0132-z · Cited by 219 · cited 1×
“Our recent studies have revealed the antiinflammatory properties of several peptide hormones such as hCG, oxytocin, ghrelin, and vasopressin.(3-6) In this review article, we focus on the anti-inflammatory properties of the incretin hormone ‘Glucagon-like Peptide-1 (GLP-1).”
BackgroundSelf-citationGlucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01112 · Cited by 218
Dubský, M., Jirkovská, A., Bem, R., Fejfarová, V., Skibová, J., Schaper, N. C., & Lipsky, B. A. (2013) · International Wound Journal · doi:10.1111/j.1742-481x.2012.01022.x · Cited by 214
Fan, Z., Aman, Y., Ahmed, I., Chetelat, G., Landeau, B., Ray Chaudhuri, K., Brooks, D. J., & Edison, P. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.016 · Cited by 212
Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210
Exendin-4 Uses Irs2 Signaling to Mediate Pancreatic β Cell Growth and Function
Park, S., Dong, X., Fisher, T. L., Dunn, S., Omer, A. K., Weir, G., & White, M. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508307200 · Cited by 208
Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207 · cited 2×
“ELISA investigation was performed at 360 min after LPS (100 ng/mL) or vehicle treatment with or without GLP-1 (1 mM) (72).”
BackgroundMethodJha, J. C., Ho, F., Dan, C., & Jandeleit-Dahm, K. (2018) · Clinical Science · doi:10.1042/cs20171459 · Cited by 205
Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204
Teramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 201 · cited 2×
“In mice with transient focal cerebral ischemia, exendin-4 treatment increased cAMP and activated the cAMP response element-binding protein (CREB) compared with vehicle-treated mice (135).”
BackgroundOxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes
Charlton, A., Garzarella, J., Jandeleit-Dahm, K. A. M., & Jha, J. C. (2020) · Biology · doi:10.3390/biology10010018 · Cited by 200
Matrix metalloproteinase-9 delays wound healing in a murine wound model
Reiss, M. J., Han, Y.-P., Garcia, E., Goldberg, M., Yu, H., & Garner, W. L. (2010) · Surgery · doi:10.1016/j.surg.2009.10.016 · Cited by 191
Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191
Bartels, A. L., Willemsen, A. T. M., Doorduin, J., de Vries, E. F. J., Dierckx, R. A., & Leenders, K. L. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.05.005 · Cited by 181
Candelario‐Jalil, E., González‐Falcón, A., García‐Cabrera, M., Álvarez, D., Al‐Dalain, S., Martínez, G., León, O. S., & Springer, J. E. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01812.x · Cited by 180 · cited 1×
“It is well known that inflammation contributes to the progression of brain damage following ischemia/reperfusion injury, and that COX-2 is a significant mediator of oxidative damage (132, 137).”
BackgroundKitazawa, M., Medeiros, R., & M. LaFerla, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799315786 · Cited by 178 · cited 1×
“In these animals, D-Ala2GIP reduces the activation of microglia and astrocytes in the brain, decreasing the release of pro-inflammatory cytokines and oxidative stress (127).”
BackgroundEffect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178
Vendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1070 · Cited by 173 · cited 1×
“confirmed the expression of GLP-1R in mature adipose cells by the detection of the mRNA and protein (58).”
BackgroundGLP-1 receptor agonists and kidney protection
Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., & De Cosmo, S. (2019) · Medicina · doi:10.3390/medicina55060233 · Cited by 173
MacMahon Copas, A. N., McComish, S. F., Fletcher, J. M., & Caldwell, M. A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.666737 · Cited by 173
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Han, Y., Li, Y., & He, B. (2019) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2019.04.017 · Cited by 159
Golpon, H. A., Puechner, A., Welte, T., Wichert, P. V., & Feddersen, C. O. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(01)00300-7 · Cited by 158
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148 · cited 1×
“Frontiers in Immunology 08 mouse model of Alzheimer’s disease reduced the inflammatory response in the cortex by decreasing the number of activated microglia (60, 65, 107, 124, 125).”
BackgroundGLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery
Richter, G., Feddersen, O., Wagner, U., Barth, P., Goke, R., & Goke, B. (1993) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1993.265.4.l374 · Cited by 146
Xu, K., Xu, Y., Brown-Jermyn, D., Chen, J.-F., Ascherio, A., Dluzen, D. E., & Schwarzschild, M. A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3008-05.2006 · Cited by 142
Lee, C., Jeon, S. J., Cho, K. S., Moon, E., Sapkota, A., Jun, H., Ryu, J. H., & Choi, J. W. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0550-2 · Cited by 136
Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
Marques, C., Mega, C., Gonçalves, A., Rodrigues-Santos, P., Teixeira-Lemos, E., Teixeira, F., Fontes-Ribeiro, C., Reis, F., & Fernandes, R. (2014) · Mediators of Inflammation · doi:10.1155/2014/538737 · Cited by 126
Wang, Y., Parlevliet, E. T., Geerling, J. J., van der Tuin, S. J. L., Zhang, H., Bieghs, V, Jawad, A. H. M., Shiri‐Sverdlov, R., Bot, I., de Jager, S. C. A., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12490 · Cited by 126 · cited 1×
“Exendin-4, a GLP-1R agonist, was shown in another study to lower hepatic production of the inflammatory markers TNF-, IL-1, and IL-6, as well as macrophage markers cluster of differentiation 68 (CD68), and F4/80 in mice fed a western-type (high fat) diet (54).”
BackgroundGlucagon‐like peptide 1 receptor stimulation as a means of neuroprotection
Harkavyi, A., & Whitton, P. S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00486.x · Cited by 125 · cited 1×
“Exogenous GLP-1 (7–36) amide administration inhibited IL-1 beta transcription and prevented beta-induced amnesia and cell death (36, 59, 113, 114).”
BackgroundThe glucagon-like peptides: a double-edged therapeutic sword?
Perry, T., & Greig, N. H. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00160-3 · Cited by 122 · cited 1×
“Furthermore, administration of the GLP-1R agonist exendin-4 in vivo and in vitro proved protective (132, 138, 139) (Figure 9).”
BackgroundDistribution of immunoassayable glucagon in gastrointestinal tissues
Unger, R. H., Ketterer, H., & Eisentraut, A. M. (1966) · Metabolism · doi:10.1016/0026-0495(66)90156-9 · Cited by 122 · cited 2×
“, developed the first antibody that could be used in a radioimmunoassay to detect glucagon in tissue samples and blood (9, 10).”
BackgroundWang, X., Zhai, Y., Xu, L., Qiao, C., Sun, X., Ding, J., Lu, M., & Hu, G. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.11.001 · Cited by 121
Marzook, A., Tomas, A., & Jones, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.678055 · Cited by 121 · cited 1×
“The transmembrane helices are connected by three extracellular and three intracellular loops (17, 18).”
BackgroundParthsarathy, V., & Hölscher, C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.012 · Cited by 119 · cited 1×
“Liraglutide reduces the proinflammatory cytokine gene expression caused by X-ray irradiation (42, 131).”
BackgroundLi, Z., Guo, S., Yao, F., Zhang, Y., & Li, T. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.12.007 · Cited by 118
Steven, S., Hausding, M., Kröller-Schön, S., Mader, M., Mikhed, Y., Stamm, P., Zinßius, E., Pfeffer, A., Welschof, P., Agdauletova, S., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0465-x · Cited by 114 · cited 1×
“Exendin-4 and DPP-4 deficiency prevented vasoconstriction and multiple organ injury after LPS treatment, and improved survival in endotoxemic rats (31).”
BackgroundSamson, S. L., Sathyanarayana, P., Jogi, M., Gonzalez, E. V., Gutierrez, A., Krishnamurthy, R., Muthupillai, R., Chan, L., & Bajaj, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2317-z · Cited by 110 · cited 1×
“Note that 80% of patients who develop hepatocellular carcinoma had cirrhosis beforehand (55, 56).”
BackgroundIMMUNOCHEMICAL GLUCAGON IN HUMAN PANCREAS, GUT, AND PLASMA
Samols, E., Tyler, J., Megyesi, C., & Marks, V. (1966) · The Lancet · doi:10.1016/s0140-6736(66)92982-5 · Cited by 109 · cited 1×
“Subsequently in 1967, Samols and Marks reported glucagon-like material in pancreatectomized humans, indicating its extra-pancreatic origin (11).”
BackgroundWang, X.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14821 · Cited by 109 · cited 3×
“10%-15% of NASH cases will develop into hepatocellular carcinoma, approximately 700,000 people die from the disease each year (53).”
BackgroundInfluentialGlucagon-like peptide-1 suppresses neuroinflammation and improves neural structure
Yoon, G., Kim, Y.-K., & Song, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104615 · Cited by 107
Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors
Spielman, L. J., Gibson, D. L., & Klegeris, A. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.03.004 · Cited by 105 · cited 1×
“Microglia and astroglia express GIP receptors (128, 129).”
BackgroundA review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
Abdalla, M. A., Deshmukh, H., Atkin, S., & Sathyapalan, T. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820938305 · Cited by 103
A Role for GLP-1 in Treating Hyperphagia and Obesity
Grill, H. J. (2020) · Endocrinology · doi:10.1210/endocr/bqaa093 · Cited by 101
1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine induced Parkinson's disease in zebrafish
Nukala, S. B., Murthy, C. L. N., Kakara, S., Sharma, R., Swamy, C. V. B., & Idris, M. M. (2016) · PROTEOMICS · doi:10.1002/pmic.201500291 · Cited by 100
Rogliani, P., Calzetta, L., Capuani, B., Facciolo, F., Cazzola, M., Lauro, D., & Matera, M. G. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0311oc · Cited by 99
GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models
Zhang, Z. Q., & Hölscher, C. (2020) · Peptides · doi:10.1016/j.peptides.2019.170184 · Cited by 99 · cited 1×
“GIP receptor activation increases microglia expression of key growth factors such as brain-derived neurotrophic factor(BDNF), glial cellline derived neurotrophic factor (GDNF), and nerve growth factor (NGF) in a phosphoinositide 3-kinase (PI3K) and protein kinase A (PKA) dependent manner (130) (Figure 6).”
BackgroundSimon, T. G., Patorno, E., & Schneeweiss, S. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.07.010 · Cited by 98 · cited 1×
“Note that 80% of patients who develop hepatocellular carcinoma had cirrhosis beforehand (55, 56).”
BackgroundTate, M., Robinson, E., Green, B. D., McDermott, B. J., & Grieve, D. J. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-015-0518-1 · Cited by 96 · cited 1×
“This was associated with a reduction in macrophage infiltration, lower expression of IL-1b and IL-6, and an increase in IL-10 in the heart (41).”
BackgroundElkind-Hirsch, K. E., Chappell, N., Seidemann, E., Storment, J., & Bellanger, D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab408 · Cited by 96
Mouës, C. M., van Toorenenbergen, A. W., Heule, F., Hop, W. C. J., & Hovius, S. E. R. (2008) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2008.00395.x · Cited by 92
Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice
Zhou, F., Zhang, Y., Chen, J., Hu, X., & Xu, Y. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.10.016 · Cited by 89
Role of Endothelial Progenitor Cells and Inflammatory Cytokines in Healing of Diabetic Foot Ulcers
Tecilazich, F., Dinh, T., Pradhan‐Nabzdyk, L., Leal, E. C., Tellechea, A., Kafanas, A., Gnardellis, C., Magargee, M. L., Dejam, A., Toxavidis, V., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083314 · Cited by 88
Toki, S., Newcomb, D. C., Printz, R. L., Cahill, K. N., Boyd, K. L., Niswender, K. D., & Peebles, R. S. (2021) · Allergy · doi:10.1111/all.14879 · Cited by 88
Xu, X., Lin, L., Chen, P., Yunjie, Y., Chen, S., Chen, X., & Shao, Z. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.03.002 · Cited by 86
Cheng, D., Yang, S., Zhao, X., & Wang, G. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s348055 · Cited by 84 · cited 2×
“GLP-1 therapy decreased IL-1b mRNA production compared to the LPS alonetreated cultures (67, 72).”
BackgroundLiraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes
Lg, S., Дігтяр, Н. І., Селіхова, Л. Г., Кайдашева, Е. І., Shlykova, O. A., Vesnina, L. E., & Кайдашев, І. П. (2019) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2019-0003 · Cited by 81
Lin, L., Xu, X., Yu, Y., Ye, H., He, X., Chen, S., Chen, X., Shao, Z., & Chen, P. (2022) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1826392 · Cited by 81
GLP-1 nanomedicine alleviates gut inflammation
Anbazhagan, A. N., Thaqi, M., Priyamvada, S., Jayawardena, D., Kumar, A., Gujral, T., Chatterjee, I., Mugarza, E., Saksena, S., Onyuksel, H., et al. (2017) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.08.004 · Cited by 80
Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds
Insuela, D. B. R., & Carvalho, V. F. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.015 · Cited by 72
Tessaro, F. H. G., Ayala, T. S., & Martins, J. O. (2015) · BioMed Research International · doi:10.1155/2015/568408 · Cited by 70
Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS
Xing, C., Li, C., & He, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa337 · Cited by 69
The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
Fukuda, M. (2021) · Diabetes · doi:10.2337/dbi21-0001 · Cited by 69 · cited 1×
“Microglia and astroglia express GIP receptors (128, 129).”
BackgroundIncretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Michałowska, J., Miller-Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 68
GOU, S., ZHU, T., WANG, W., XIAO, M., WANG, X.-C., & CHEN, Z.-H. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.07.010 · Cited by 66
Arakawa, M., Ebato, C., Mita, T., Hirose, T., Kawamori, R., Fujitani, Y., & Watada, H. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.054 · Cited by 65
Hunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021) · Biomedicines · doi:10.3390/biomedicines9040383 · Cited by 65 · cited 3×
“GLP-1 decreases production of pro-inflammatory cytokines, mainly by downregulating NF-kB phosphorylation and nuclear translocation (45).”
BackgroundInfluentialLiu, L., Arun, A., Ellis, L., Peritore, C., & Donmez, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00184 · Cited by 63
Increased expression of glucagon‐like peptide‐1 receptors in psoriasis plaques
Faurschou, A., Pedersen, J., Gyldenløve, M., Poulsen, S. S., Holst, J. J., Thyssen, J. P., Zachariae, C., Vilsbøll, T., Skov, L., & Knop, F. K. (2013) · Experimental Dermatology · doi:10.1111/exd.12081 · Cited by 63
Cao, B., Zhang, Y., Chen, J., Wu, P., Dong, Y., & Wang, Y. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00879-1 · Cited by 62
Marlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12974 · Cited by 61
Gupta, N. A., Kolachala, V. L., Jiang, R., Abramowsky, C., Romero, R., Fifadara, N., Anania, F., Knechtle, S., & Kirk, A. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.07.015 · Cited by 60 · cited 1×
“The ability of GLP-1 to reduce fat is due to its binding to a specific GLP-1R present in adipose tissue (57).”
BackgroundEffect of liraglutide on expression of inflammatory genes in type 2 diabetes
Zobel, E. H., Ripa, R. S., von Scholten, B. J., Rotbain Curovic, V., Kjaer, A., Hansen, T. W., Rossing, P., & Størling, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-97967-0 · Cited by 59
Ma, R.-L., Deng, Y., Wang, Y.-F., Zhu, S.-Y., Ding, X.-S., & Sun, A.-J. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001712 · Cited by 59
Ferrari, F., Moretti, A., & Villa, R. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108277 · Cited by 59
Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma
Nguyen, D.-V., Linderholm, A., Haczku, A., & Kenyon, N. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.06.012 · Cited by 57
Kim, S., Jeong, J., Jung, H.-S., Kim, B., Kim, Y.-E., Lim, D.-S., Kim, S.-D., & Song, Y. S. (2017) · Experimental Neurobiology · doi:10.5607/en.2017.26.4.227 · Cited by 57 · cited 6×
“tMCAO, Transient middle cerebral artery occlusion (132): 1-The level of COX-2 was significantly increased at 48 h after tMCAO.”
BackgroundInfluentialGlucagon-like Peptide-1(7–36) Amide Stimulates Surfactant Secretion in Human Type II Pneumocytes
VARA, E., ARIAS-DÍAZ, J., GARCIA, C., BALIBREA, J. L., & BLÁZQUEZ, E. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.4.9912132 · Cited by 56
The Family B1 GPCR: Structural Aspects and Interaction with Accessory Proteins
Couvineau, A., & Laburthe, M. (2011) · Current Drug Targets · doi:10.2174/138945012798868434 · Cited by 56
GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
Li, Q.-X., Gao, H., Guo, Y.-X., Wang, B.-Y., Hua, R.-X., Gao, L., Shang, H.-W., Lu, X., & Xu, J.-D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721198 · Cited by 56 · cited 1×
“GLP-1 therapies may have preventive and restorative effects on Alzheimer’s disease (42, 119).”
BackgroundBéjot, Y., & Giroud, M. (2010) · Diabetes & Metabolism · doi:10.1016/s1262-3636(10)70472-9 · Cited by 55 · cited 1×
“Patients who have hyperglycemia and diabetes mellitus type 2 (T2DM) have a higher stroke frequency than those who do not have these conditions (132, 133).”
BackgroundWiera, G., Nowak, D., van Hove, I., Dziegiel, P., Moons, L., & Mozrzymas, J. W. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2170-16.2016 · Cited by 55
Zatorski, H., Sałaga, M., & Fichna, J. (2019) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-019-01698-z · Cited by 55 · cited 4×
“The Incidence and prevalence of IBDs are rising globally.”
BackgroundInfluentialGhrelin as an Anti-Sepsis Peptide: Review
Mathur, N., Mehdi, S. F., Anipindi, M., Aziz, M., Khan, S. A., Kondakindi, H., Lowell, B., Wang, P., & Roth, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.610363 · Cited by 54
Self-citationExendin-4 Protects Hypoxic Islets From Oxidative Stress and Improves Islet Transplantation Outcome
Padmasekar, M., Lingwal, N., Samikannu, B., Chen, C., Sauer, H., & Linn, T. (2013) · Endocrinology · doi:10.1210/en.2012-1983 · Cited by 53 · cited 1×
“Exendin-4 suppresses oxidative stress, inducible nitric oxide synthase (iNOS) expression, and cellular apoptosis after ischemia/reperfusion injury (135, 136).”
BackgroundHelmstädter, J., Keppeler, K., Aust, F., Küster, L., Frenis, K., Filippou, K., Vujacic-Mirski, K., Tsohataridis, S., Kalinovic, S., Kröller-Schön, S., et al. (2021) · Antioxidants · doi:10.3390/antiox10081175 · Cited by 53 · cited 2×
“In a polymicrobial model of sepsis induced by cecal ligation and puncture, a GLP-1 analog ameliorated vascular inflammation and oxidative stress by improving endothelial function (28) In a cardiac fibrosis model, the GLP-1 analogue liraglutide reduced vascular reactivity, cardiac hypertrophy, fibroblast accumulation,…”
BackgroundExendin‐4 Therapy in NOD Mice with New‐Onset Diabetes Increases Regulatory T Cell Frequency
Xue, S., Wasserfall, C. H., Parker, M., Brusko, T. M., McGrail, S., McGrail, K., Moore, M., Campbell‐Thompson, M., Schatz, D. A., Atkinson, M. A., et al. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1447.049 · Cited by 51 · cited 1×
“Exendin in diabetic mice diminishes inflammatory responses by increasing the expression of regulatory T cells (32).”
BackgroundYin, W., Xu, S., Wang, Z., Liu, H., Peng, L., Fang, Q., Deng, T., Zhang, W., & Lou, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.076 · Cited by 51
Chronic peripheral inflammation: a possible contributor to neurodegenerative diseases
Schlachetzki, J. M., Süβ, P., & Lana, A. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306060 · Cited by 51
Costanzo, G., Curatolo, S., Busà, B., Belfiore, A., & Gullo, D. (2021) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-21-0007 · Cited by 51
Gaspari, T., Brdar, M., Lee, H. W., Spizzo, I., Hu, Y., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115605000 · Cited by 49 · cited 1×
“In a polymicrobial model of sepsis induced by cecal ligation and puncture, a GLP-1 analog ameliorated vascular inflammation and oxidative stress by improving endothelial function (28) In a cardiac fibrosis model, the GLP-1 analogue liraglutide reduced vascular reactivity, cardiac hypertrophy, fibroblast accumulation,…”
BackgroundGLP-1 Receptor: A New Target for Sepsis
Yang, F., Zeng, F., Luo, X., Lei, Y., Li, J., Lu, S., Huang, X., Lan, Y., & Liu, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.706908 · Cited by 48
Oxytocin and Related Peptide Hormones: Candidate Anti-Inflammatory Therapy in Early Stages of Sepsis
Mehdi, S. F., Pusapati, S., Khenhrani, R. R., Farooqi, M. S., Sarwar, S., Alnasarat, A., Mathur, N., Metz, C. N., LeRoith, D., Tracey, K. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864007 · Cited by 48
Self-citationEffect of glucagon-like peptide-1 receptor agonists in patients with psoriasis
Al-Badri, M. R., & Azar, S. T. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814543483 · Cited by 47
Diabetes mellitus and Parkinson’s disease: dangerous liaisons between insulin and dopamine
Colosimo, C., Iuliis, A. D., Montinaro, E., Fatati, G., & Plebani, M. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320965 · Cited by 47
Kawamori, D., Shirakawa, J., Liew, C. W., Hu, J., Morioka, T., Duttaroy, A., Burkey, B., & Kulkarni, R. N. (2017) · Diabetologia · doi:10.1007/s00125-017-4303-6 · Cited by 46
Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation
Vianna, A. R. D. C. B., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0059-4 · Cited by 46 · cited 1×
“Frontiers in Immunology 08 mouse model of Alzheimer’s disease reduced the inflammatory response in the cortex by decreasing the number of activated microglia (60, 65, 107, 124, 125).”
BackgroundLao, G., Ren, M., Wang, X., Zhang, J., Huang, Y., Liu, D., Luo, H., Yang, C. H., & Li, Y. (2017) · Experimental Dermatology · doi:10.1111/exd.13442 · Cited by 46
Rebosio, C., Balbi, M., Passalacqua, M., Ricciarelli, R., & Fedele, E. (2018) · BioFactors · doi:10.1002/biof.1406 · Cited by 46
Benito, E., Blázquez, E., & Bosch, M. A. (1998) · Endocrinology · doi:10.1210/en.139.5.2363 · Cited by 45
Lin, C.-H., & LIN, C.-C. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3255 · Cited by 45
López‐Cano, C., Ciudin, A., Sánchez, E., Tinahones, F. J., Barbé, F., Dalmases, M., García‐Ramírez, M., Soto, A., Gaeta, A. M., Pellitero, S., et al. (2021) · Diabetes · doi:10.2337/db21-0688 · Cited by 45
Su, Y., Liu, N., Zhang, Z., Li, H., Ma, J., Yuan, Y., Shi, M., Liu, J., Zhao, Z., Zhang, Z., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175029 · Cited by 44
GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptor
Fusco, J., Xiao, X., Prasadan, K., Sheng, Q., Chen, C., Ming, Y.-C., & Gittes, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-09898-4 · Cited by 43
Zhu, T., Li, C., Zhang, X., Ye, C., Tang, S., Zhang, W., Sun, J., Huang, N., Wen, F., Wang, D., et al. (2018) · Mediators of Inflammation · doi:10.1155/2018/3601454 · Cited by 42
Lu, C., Xie, T., Guo, X., Wu, D., Li, S., Li, X., Lu, Y., & Wang, X. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105969 · Cited by 40
Manavi, M. A. (2022) · Neuropeptides · doi:10.1016/j.npep.2022.102250 · Cited by 40
Fandiño, J., Vaz, A. A., Toba, L., Romaní-Pérez, M., González-Matías, L., Mallo, F., & Diz-Chaves, Y. (2018) · International Journal of Endocrinology · doi:10.1155/2018/6920620 · Cited by 39
Diz-Chaves, Y., Toba, L., Fandiño, J., González-Matías, L. C., Garcia-Segura, L. M., & Mallo, F. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1370-7 · Cited by 38 · cited 1×
“Frontiers in Immunology 08 mouse model of Alzheimer’s disease reduced the inflammatory response in the cortex by decreasing the number of activated microglia (60, 65, 107, 124, 125).”
BackgroundAl-Dwairi, A., Alqudah, T., Al-Shboul, O., Alqudah, M., Mustafa, A., & Alfaqih, M. A. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s152835 · Cited by 37
Wolak, M., Staszewska, T., Juszczak, M., Gałdyszyńska, M., & Bojanowska, E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.053 · Cited by 37
Fernandez, E. D. T., Huffman, A. M., Syed, M., Romero, D. G., & Cardozo, L. L. Y. (2019) · Endocrinology · doi:10.1210/en.2019-00450 · Cited by 37
Huang, J., Liu, Y., Cheng, L., Li, J., Zhang, T., Zhao, G., & Zhang, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173581 · Cited by 36 · cited 1×
“The peptide improved memory and prevented the loss of hippocampal neurons (111, 123).”
BackgroundExendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPARγ-FOXA2-phosphatase signaling
Choi, W., Choe, S., Lin, J., Borchers, M. T., Kosmider, B., Vassallo, R., Limper, A. H., & Lau, G. W. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-0262-1 · Cited by 35
Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., & Mallo, F. (2022) · Vitamins and hormones · doi:10.1016/bs.vh.2021.12.005 · Cited by 35 · cited 1×
“Frontiers in Immunology 08 mouse model of Alzheimer’s disease reduced the inflammatory response in the cortex by decreasing the number of activated microglia (60, 65, 107, 124, 125).”
BackgroundThe GLP-1 receptor in airway inflammation in asthma: a promising novel target?
Wu, A. Y., & Peebles, R. S. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1971973 · Cited by 34 · cited 3×
“GLP-1 receptor agonists decreased allergic responses in asthma by preventing the activation of NF-kB leading to decreased release of proinflammatory cytokines (IL-5, IL-13, IL-33) and neutrophils, eosinophils, basophils and CD4 + T cell numbers (142, 145).”
BackgroundInfluentialShah, F. A., Mahmud, H., Gallego‐Martin, T., Jurczak, M. J., O'Donnell, C. P., & McVerry, B. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00296 · Cited by 33
[The population incidence of warts].
Beliaeva, T. L. (1990) · PubMed · Cited by 31
Wander, P. L., Lowy, E., Beste, L. A., Tulloch-Palomino, L. G., Korpak, A. M., Peterson, A. C., Kahn, S. E., & Boyko, E. J. (2021) · Diabetes Care · doi:10.2337/dc21-1351 · Cited by 28
Farshchian, M., Ansar, A., Sobhan, M., & Hoseinpoor, V. (2016) · Anais Brasileiros de Dermatologia · doi:10.1590/abd1806-4841.20164655 · Cited by 27
Öztay, F., Sancar‐Baş, S., Gezginci-Oktayoğlu, S., Erçin, M., & Bolkent, Ş. (2017) · Peptides · doi:10.1016/j.peptides.2017.12.007 · Cited by 25
Skurikhin, Е. G., Pershina, О. V., Pakhomova, A. V., Pan, E. S., Krupin, V. A., Ermakova, N. N., Ваизова, О. Е., Pozdeeva, A. S., Zhukova, М. А., Skurikhina, V. E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051105 · Cited by 25
MAJESKI, J. A. (1978) · JAMA · doi:10.1001/jama.240.14.1508 · Cited by 22
Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
C. Sourris, K., Yao, H., Jerums, G., E.Cooper, M., I. Ekinci, E., & T. Coughlan, M. (2016) · Current Drug Targets · doi:10.2174/1389450116666150722141418 · Cited by 21
Changes in biological behaviors of rat dermal fibroblasts induced by high expression of MMP9
Xue, S., Lei, J., Lin, D., Yang, C. H., & Yan, L. (2014) · World Journal of Emergency Medicine · doi:10.5847/wjem.j.issn.1920-8642.2014.02.011 · Cited by 21
Liljedahl, L., Pedersen, M. H., McGuire, J. N., & James, P. (2019) · Physiological Reports · doi:10.14814/phy2.13994 · Cited by 21
Bai, Y., Lian, P., Li, J., Zhang, Z., & Jian, Q. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104645 · Cited by 21
Choi, J. H., Kim, S.-J., Kwon, S. K., Kim, H., & Jeon, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236024 · Cited by 20
Attenuated Postprandial GLP-1 Response in Parkinson’s Disease
Manfready, R. A., Engen, P. A., Verhagen Metman, L., Sanzo, G., Goetz, C. G., Hall, D. A., Forsyth, C. B., Raeisi, S., Voigt, R. M., & Keshavarzian, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.660942 · Cited by 19 · cited 1×
“The intraventricular administration of GLP-1 protects mice from MPTP-induced dopaminergic cell loss (64, 86, 108, 109).”
BackgroundYang, X., Ma, X., Don, O., Song, Y., Chen, X., Liu, J., Qu, J., & Feng, Y. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01689-5 · Cited by 18
Zhu, M., & Gong, D. (2020) · Medical Science Monitor · doi:10.12659/msm.920989 · Cited by 16
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Mechanisms of long COVID and the path toward therapeutics
Peluso, M. J., & Deeks, S. G. (2024) · Cell · doi:10.1016/j.cell.2024.07.054 · Cited by 341
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“69,70 Liraglutide has been shown to modulate immune responses in individuals with diabetes.”
BackgroundBrain-wide cell-type-specific transcriptomic signatures of healthy ageing in mice
Jin, K., Yao, Z., van Velthoven, C. T. J., Kaplan, E. S., Glattfelder, K. J., Barlow, S. T., Boyer, G., Carey, D., Casper, T., Chakka, A. B., et al. (2025) · Nature · doi:10.1038/s41586-024-08350-8 · Cited by 185
Unveiling Gestational Diabetes: An Overview of Pathophysiology and Management
Mittal, R., Prasad, K., Lemos, J. R. N., Arevalo, G., & Hirani, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052320 · Cited by 181
“Beyond their metabolic effects, emerging evidence suggests that GLP-1R agonists may exert anti-inflammatory properties [345–347].”
Metadata
- Authors
- Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M. J., & Roth, J.
- Affiliations
- Northwell Health (US)
- Icahn School of Medicine at Mount Sinai (US)
- Azevan Pharmaceuticals (United States) (US)
- Corresponding author
- Roth, Jesse
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-05-17
- Volume
- 14
- Pages
- 1148209-1148209
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC10230051
- OpenAlex
- W4377041419
- Cited by
- 317
- References
- 208
- Citations by year
- 2026: 107 · 2025: 138 · 2024: 61 · 2023: 10
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Feinstein Institutes for Medical Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, anti-inflammatory peptides, inflammation, sepsis, inflammatory cytokines, type 2 diabetes, metabolic syndrome, hyperglycemia, HbA1c, apoptosis, cardioprotection, neuroprotection, adjuvant therapy
- MeSH terms
- Anti-Inflammatory Agents, Diabetes Mellitus, Type 2, Humans, Inflammation, Peptides, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.